Prevention of Myopia of Prematurity by Calcium Supplementation

NCT ID: NCT00892476

Last Updated: 2012-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-02-28

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if supplementation of calcium by the enteral route (gut feeding) to extremely low birth weight infants will lead to less myopia (nearsightedness) at 6-12 months postnatal age.

Secondly, the study will determine if calcium supplementation is well tolerated, if it reduces the molding of these premature infants' heads, and if it decreases myopia at the 18-22 month postnatal age visit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All infants admitted meeting the 401-1000gm birthweight and less than 14 day of age entry criteria will be screened for entry into the study. Infants may be excluded for the following: Major congenital malformations, including complex congenital heart disease (except open ductus arteriosus, atrial and ventricular septal defects), pulmonary malformations, bowel or anal stenosis or atresia, renal dysplasias, chromosomal anomalies, hydrops fetalis, bowel perforation or necrotizing enterocolitis stage 2A or greater before randomization.

Written informed consent of one parent or legal guardian must be obtained. The infants are randomized to receive unsupplemented feedings of breast milk or formula, or feedings supplemented with Ca-gluconate as outlined below.

Randomization will be stratified into the following groups: 401-750 g and 751-1000 g and performed according to a balanced block scheme with variable block size (2-6) using sealed opaque envelopes.

Total parenteral nutrition is given by nursery unit standards. Infant positioning is done by nursery unit standards.

Feeding mixtures:

Supplementation is started when enteral feeding amounts to 100 ml/kg. At that time, fortification is also introduced in infants receiving breast milk. Fortified human milk or 24 cal/oz formula, e.g. Similac Special Care 24 (SSC24), is used in all participating infants. Human milk is fortified with 1 pk Enfamil human milk fortifier per 25 ml (BMHMF).

Control group: Fortified human milk or 24 cal/oz formula. Supplemented group: Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons (e.g. Rubbermaid (R)) and added to the feeding mixtures.

One eye exam will be performed at 6-12 months during routine follow-up visit. A second eye exam will be performed at 18-2 months during a follow-up visit which is part of the NICHD newborn follow-up clinic. Head measurements, specifically, front-to-back and side-to-side will be measured at randomization, 36 weeks postmenstrual age or discharge, whichever occurs first, and during the follow up visits. Urinalysis will be collected weekly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

myopia calcium supplementation prematurity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.

Group Type EXPERIMENTAL

Calcium Supplementation

Intervention Type DIETARY_SUPPLEMENT

Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:

Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g

25 ml ¼ tsp 1/8 tsp

50 ml ½ tsp ¼ tsp

100 ml 1 tsp ½ tsp

200 ml 2 tsp 1 tsp

2

Infants will receive fortified breast milk or 24 cal/oz formula

Group Type ACTIVE_COMPARATOR

Standard of Care

Intervention Type OTHER

Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Calcium Supplementation

Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:

Amount of feeding Actual Weight \< 1000 g Actual Weight \< 1000 g

25 ml ¼ tsp 1/8 tsp

50 ml ½ tsp ¼ tsp

100 ml 1 tsp ½ tsp

200 ml 2 tsp 1 tsp

Intervention Type DIETARY_SUPPLEMENT

Standard of Care

Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

USP grade Calcium gluconate powder from Sigma Chemical Company (Cat # C-8231, St. Louis, MO)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants with a birthweight of 401 - 1000 g and postnatal age less than 14 days

Exclusion Criteria

* Major congenital malformations including

* complex congenital heart disease (except open ductus arteriosus, atrial and ventricular septal defects)
* pulmonary malformations
* bowel or anal stenosis or atresia
* renal dysplasias
* chromosomal anomalies
* hydrops fetalis
* bowel perforation or necrotizing enterocolitis stage 2A or greater before randomization.
Minimum Eligible Age

1 Day

Maximum Eligible Age

14 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alabama at Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Waldemar Carlo, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

References

Explore related publications, articles, or registry entries linked to this study.

Carroll WF, Fabres J, Nagy TR, Frazier M, Roane C, Pohlandt F, Carlo WA, Thome UH. Results of extremely-low-birth-weight infants randomized to receive extra enteral calcium supply. J Pediatr Gastroenterol Nutr. 2011 Sep;53(3):339-45. doi: 10.1097/MPG.0b013e3182187ecd.

Reference Type DERIVED
PMID: 21865980 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

F010613009

Identifier Type: -

Identifier Source: org_study_id